Norbert Riedel - Jan 4, 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role
Director
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol
CERE
Transactions as of
Jan 4, 2022
Transactions value $
$0
Form type
4
Date filed
1/6/2022, 03:31 PM
Previous filing
Dec 8, 2021
Next filing
Feb 28, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise +14.3K +50% 42.8K Jan 4, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Restricted Stock Units Options Exercise $0 -14.3K -100% $0.00* 0 Jan 4, 2022 Common Stock 14.3K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock.
F2 14,270 RSUs vested on January 4, 2022, the third anniversary of the vesting commencement date of January 4, 2019.